HRT and Breast Cancer: The Absolute Numbers
SaveCombined estrogen-plus-progestin therapy adds roughly 8 breast cancers per 10,000 women a year, fewer than 1 in 1,000. Estrogen-alone therapy does not appear to raise risk and may slightly lower it. The added risk rises with longer use and varies with age, family history, and breast density.
Last updated: July 2026
How much does HRT raise breast cancer risk?
Combined estrogen-plus-progestin therapy raises breast cancer risk by a small absolute amount, while estrogen-alone therapy does not appear to. In the Women's Health Initiative, combined therapy produced roughly 8 additional invasive breast cancers per 10,000 women for each year of use 1Ref 1Chlebowski RT, Anderson GL, Aragaki AK, et al. (2020).Association of menopausal hormone therapy with breast cancer incidence and mortality during long-term follow-up of the Women's Health Initiative randomized clinical trials.Long-term WHI follow-up (about 20 years) quantifying breast cancer incidence by regimen: combined therapy raised it, estrogen alone lowered it slightly.2Ref 2Rossouw JE, Anderson GL, Prentice RL, et al. / Writing Group for the Women's Health Initiative Investigators (2002).Risks and benefits of estrogen plus progestin in healthy postmenopausal women: principal results from the Women's Health Initiative randomized controlled trial.The WHI per-10,000 absolute count of roughly 8 additional invasive breast cancers per year with combined therapy.. Put in per-person terms, that is fewer than 1 in 1,000 women each year.
Over about 20 years of follow-up, women who took estrogen alone after a hysterectomy showed slightly fewer breast cancers than those on placebo 1Ref 1Chlebowski RT, Anderson GL, Aragaki AK, et al. (2020).Association of menopausal hormone therapy with breast cancer incidence and mortality during long-term follow-up of the Women's Health Initiative randomized clinical trials.Long-term WHI follow-up (about 20 years) quantifying breast cancer incidence by regimen: combined therapy raised it, estrogen alone lowered it slightly.3Ref 3Anderson GL, Limacher M, Assaf AR, et al. / Women's Health Initiative Steering Committee (2004).Effects of conjugated equine estrogen in postmenopausal women with hysterectomy: the Women's Health Initiative randomized controlled trial.The WHI estrogen-alone arm in women with hysterectomy, showing no increase in breast cancer.. According to the North American Menopause Society, the absolute increase from combined therapy is small and depends heavily on age, duration, and personal risk factors 4Ref 4The North American Menopause Society (Menopause Society) (2022).The 2022 Hormone Therapy Position Statement of The North American Menopause Society.Consensus that the absolute breast cancer increase from combined therapy is small, rises with duration, and has no arbitrary stopping date.. The number many women fear looms far larger in headlines than in a real clinic.
What separates estrogen-alone from combined therapy?
Estrogen-alone and combined therapy carry meaningfully different breast cancer signals. Women who still have a uterus need a progestogen alongside estrogen to protect the uterine lining, and it is the progestogen component that appears to drive most of the added breast cancer risk 1Ref 1Chlebowski RT, Anderson GL, Aragaki AK, et al. (2020).Association of menopausal hormone therapy with breast cancer incidence and mortality during long-term follow-up of the Women's Health Initiative randomized clinical trials.Long-term WHI follow-up (about 20 years) quantifying breast cancer incidence by regimen: combined therapy raised it, estrogen alone lowered it slightly.4Ref 4The North American Menopause Society (Menopause Society) (2022).The 2022 Hormone Therapy Position Statement of The North American Menopause Society.Consensus that the absolute breast cancer increase from combined therapy is small, rises with duration, and has no arbitrary stopping date.. In long-term WHI follow-up spanning about 20 years, combined therapy raised breast cancer incidence, whereas conjugated estrogen alone lowered it by a small margin in women who had had a hysterectomy 1Ref 1Chlebowski RT, Anderson GL, Aragaki AK, et al. (2020).Association of menopausal hormone therapy with breast cancer incidence and mortality during long-term follow-up of the Women's Health Initiative randomized clinical trials.Long-term WHI follow-up (about 20 years) quantifying breast cancer incidence by regimen: combined therapy raised it, estrogen alone lowered it slightly.3Ref 3Anderson GL, Limacher M, Assaf AR, et al. / Women's Health Initiative Steering Committee (2004).Effects of conjugated equine estrogen in postmenopausal women with hysterectomy: the Women's Health Initiative randomized controlled trial.The WHI estrogen-alone arm in women with hysterectomy, showing no increase in breast cancer..
This distinction reshaped how clinicians counsel women considering hormone therapy for menopause. According to the 2022 society statement, the type of progestogen and the route of delivery may further modify the signal, though head-to-head data remain limited 4Ref 4The North American Menopause Society (Menopause Society) (2022).The 2022 Hormone Therapy Position Statement of The North American Menopause Society.Consensus that the absolute breast cancer increase from combined therapy is small, rises with duration, and has no arbitrary stopping date.. Estrogen alone is not simply a lower dose of the same risk.
Why do relative-risk headlines sound scarier?
Relative risk and absolute risk describe the same finding in very different emotional registers. A headline that says HRT raises breast cancer risk by roughly a quarter sounds frightening, yet the WHI's actual increase came to fewer than 1 in 1,000 women a year 1Ref 1Chlebowski RT, Anderson GL, Aragaki AK, et al. (2020).Association of menopausal hormone therapy with breast cancer incidence and mortality during long-term follow-up of the Women's Health Initiative randomized clinical trials.Long-term WHI follow-up (about 20 years) quantifying breast cancer incidence by regimen: combined therapy raised it, estrogen alone lowered it slightly.. A woman's baseline breast cancer risk over 5 years is already shaped by age, family history, and breast density, which a single percentage ignores 5Ref 5Beral V / Million Women Study Collaborators (2003).Breast cancer and hormone-replacement therapy in the Million Women Study.The Million Women Study observational cohort reporting higher relative breast cancer estimates than the randomized trials..
The Million Women Study, a large observational cohort, reported higher relative estimates than the randomized trials, partly because observational designs cannot fully separate hormone users from non-users 5Ref 5Beral V / Million Women Study Collaborators (2003).Breast cancer and hormone-replacement therapy in the Million Women Study.The Million Women Study observational cohort reporting higher relative breast cancer estimates than the randomized trials.. According to breast cancer researchers, absolute numbers, cases per 1,000 women, convey personal risk more honestly than percentages 1Ref 1Chlebowski RT, Anderson GL, Aragaki AK, et al. (2020).Association of menopausal hormone therapy with breast cancer incidence and mortality during long-term follow-up of the Women's Health Initiative randomized clinical trials.Long-term WHI follow-up (about 20 years) quantifying breast cancer incidence by regimen: combined therapy raised it, estrogen alone lowered it slightly.. Women managing hot flashes deserve that clearer framing.
Does the risk change with how long you use it?
Duration matters more than the simple fact of ever using hormone therapy. The added breast cancer risk from combined therapy is small in the first 3 to 5 years and rises gradually with longer use 1Ref 1Chlebowski RT, Anderson GL, Aragaki AK, et al. (2020).Association of menopausal hormone therapy with breast cancer incidence and mortality during long-term follow-up of the Women's Health Initiative randomized clinical trials.Long-term WHI follow-up (about 20 years) quantifying breast cancer incidence by regimen: combined therapy raised it, estrogen alone lowered it slightly.4Ref 4The North American Menopause Society (Menopause Society) (2022).The 2022 Hormone Therapy Position Statement of The North American Menopause Society.Consensus that the absolute breast cancer increase from combined therapy is small, rises with duration, and has no arbitrary stopping date.. Risk also appears to decline after stopping, though some elevation can persist for several years 1Ref 1Chlebowski RT, Anderson GL, Aragaki AK, et al. (2020).Association of menopausal hormone therapy with breast cancer incidence and mortality during long-term follow-up of the Women's Health Initiative randomized clinical trials.Long-term WHI follow-up (about 20 years) quantifying breast cancer incidence by regimen: combined therapy raised it, estrogen alone lowered it slightly..
Across the lifespan, a woman using short-term therapy for hot flashes in her early fifties faces a different calculus than one continuing combined hormones past age 60 4Ref 4The North American Menopause Society (Menopause Society) (2022).The 2022 Hormone Therapy Position Statement of The North American Menopause Society.Consensus that the absolute breast cancer increase from combined therapy is small, rises with duration, and has no arbitrary stopping date.. According to the North American Menopause Society, there is no arbitrary stopping date; duration is revisited periodically against symptoms and individual risk 4Ref 4The North American Menopause Society (Menopause Society) (2022).The 2022 Hormone Therapy Position Statement of The North American Menopause Society.Consensus that the absolute breast cancer increase from combined therapy is small, rises with duration, and has no arbitrary stopping date.. Reviewing the numbers alongside your own breast health history makes the tradeoff concrete.
When HRT breast cancer numbers need a clinician
A clinician who counsels on menopause can translate these population numbers into your personal risk. Your family history, breast density, age, and reasons for considering therapy all move the absolute risk up or down in ways a single statistic cannot.
A gynecologist, menopause specialist, or primary care clinician can weigh combined versus estrogen-alone therapy, discuss duration, and coordinate breast cancer screening. Gale can help you prepare for that conversation. Understanding that the added risk is measured in cases per 1,000, not in dramatic percentages, often changes how the decision feels.
Common questions
Related
Menopause & midlife
HRT With Family History: Weighing Personal RiskMenopause & midlife
HRT and Heart Disease: The Timing HypothesisMenopause & midlife
HRT With Migraine Aura: What Guidelines Say
Say it back
How would you explain this to someone you love?
Two or three sentences, just as you’d say it. Gale reflects back what you focused on — a mirror, not a quiz.
When breast changes warrant clinician review
- —A new breast lump, thickening, or area of firmness that persists is a reason to seek clinician review.
- —Skin dimpling, nipple retraction, or bloody nipple discharge is a reason to seek prompt clinician evaluation.
- —Unexplained vaginal bleeding while on combined hormone therapy is a reason to arrange a gynecologic evaluation.
- —A missed or overdue mammogram in a woman on hormone therapy is a reason to schedule screening with a clinician.
This article is general health education, not medical advice. Whether hormone therapy fits your breast cancer risk is a decision to make with a gynecologist, menopause specialist, or primary care clinician who knows your history.
References
- 1.Chlebowski RT, Anderson GL, Aragaki AK, et al. (2020). Association of menopausal hormone therapy with breast cancer incidence and mortality during long-term follow-up of the Women's Health Initiative randomized clinical trials. JAMA. doi:10.1001/jama.2020.9482 ✓Long-term WHI follow-up (about 20 years) quantifying breast cancer incidence by regimen: combined therapy raised it, estrogen alone lowered it slightly.
- 2.Rossouw JE, Anderson GL, Prentice RL, et al. / Writing Group for the Women's Health Initiative Investigators (2002). Risks and benefits of estrogen plus progestin in healthy postmenopausal women: principal results from the Women's Health Initiative randomized controlled trial. JAMA. doi:10.1001/jama.288.3.321 ✓The WHI per-10,000 absolute count of roughly 8 additional invasive breast cancers per year with combined therapy.
- 3.Anderson GL, Limacher M, Assaf AR, et al. / Women's Health Initiative Steering Committee (2004). Effects of conjugated equine estrogen in postmenopausal women with hysterectomy: the Women's Health Initiative randomized controlled trial. JAMA. doi:10.1001/jama.291.14.1701 ✓The WHI estrogen-alone arm in women with hysterectomy, showing no increase in breast cancer.
- 4.The North American Menopause Society (Menopause Society) (2022). The 2022 Hormone Therapy Position Statement of The North American Menopause Society. Menopause. doi:10.1097/GME.0000000000002028 ✓Consensus that the absolute breast cancer increase from combined therapy is small, rises with duration, and has no arbitrary stopping date.
- 5.Beral V / Million Women Study Collaborators (2003). Breast cancer and hormone-replacement therapy in the Million Women Study. Lancet. doi:10.1016/s0140-6736(03)14065-2 ✓The Million Women Study observational cohort reporting higher relative breast cancer estimates than the randomized trials.
5 sources, numbered by first appearance. General health information, not medical advice. AI-assisted editorial content — every citation independently verified. Editorial policy